IngredientesLa pectina de cítricos es un polisacárido complejo de origen natural extraído de las cáscaras, la pulpa y las cortezas de frutas cítricas como naranjas, limones, limas y pomelos. Pertenece a una clase de fibras dietéticas solubles conocidas como pectinas, que forman una sustancia gelatinosa en agua y son ampliamente utilizadas en la industria alimentaria como espesante, estabilizador y agente gelificante—particularmente en mermeladas, jaleas y conservas de frutas.
Desde el punto de vista nutricional y medicinal, la pectina de cítricos es valorada por sus beneficios digestivos, desintoxicantes y para la salud cardiovascular. Ayuda a regular los movimientos intestinales, reducir el apetito y apoyar el control del azúcar en sangre al ralentizar el vaciado gástrico y la absorción de carbohidratos. Como fibra soluble, se une al colesterol y los ácidos biliares, ayudando a reducir el colesterol LDL y mejorar los perfiles lipídicos.
Una versión modificada conocida como Pectina de Cítricos Modificada (MCP) ha sido procesada enzimáticamente para reducir su tamaño molecular y mejorar su absorción en el torrente sanguíneo. El MCP es la forma más comúnmente utilizada en entornos de medicina clínica y funcional. Ha mostrado resultados prometedores en el apoyo a la desintoxicación, la regulación inmunitaria, la actividad anti-metastásica y el control de la inflamación. El MCP es estudiado particularmente por su capacidad de unirse a la galectina-3, una proteína involucrada en la inflamación, la fibrosis y la progresión de ciertos cánceres. Al inhibir la galectina-3, el MCP puede reducir la diseminación tumoral, la cicatrización cardiovascular y la fibrosis orgánica.
Además, la pectina de cítricos puede actuar como un prebiótico, promoviendo el crecimiento de bacterias intestinales beneficiosas y apoyando la salud digestiva en general. Generalmente es bien tolerada, aunque las dosis altas pueden causar hinchazón o malestar gastrointestinal en personas sensibles.
Uso Histórico
Aunque el concepto de pectina aislada es moderno, el uso de cáscaras de cítricos y fibras de frutas con fines medicinales y culinarios se remonta a miles de años. En sistemas de medicina tradicional, como el Ayurveda, la Medicina Tradicional China (TCM) y la curación grecoareábiga, las cáscaras de cítricos se utilizaban para mejorar la digestión, reducir la flema, calmar el estómago y regular la eliminación. Estos efectos se debían en parte al contenido natural de pectina y fibra de las cáscaras.
En la Europa medieval, la cáscara de cítricos se conservaba en azúcar y se consumía para facilitar la digestión después de las comidas. Esta práctica no solo tenía un propósito culinario, sino que también aportaba una fuente suave de fibra y compuestos aromáticos que calmaban el intestino y estimulaban el flujo biliar. Los jarabes y mermeladas de cítricos—ricos en pectina natural—eran a veces recetados para el estreñimiento, la inflamación y la digestión lenta.
La pectina fue aislada por primera vez a principios del siglo XIX por científicos que estudiaban conservas de frutas. Fue identificada como el agente gelificante clave responsable de la textura espesa de las mermeladas. En el siglo XX, comenzó la producción comercial de pectina, con las cáscaras de cítricos convirtiéndose en una fuente primaria debido a su alto contenido de pectina y la abundante disponibilidad de subproductos del procesamiento de jugos.
Hoy en día, la pectina de cítricos, especialmente en su forma modificada, se utiliza en oncología integrativa, terapia cardiovascular y protocolos de desintoxicación, uniendo el uso tradicional de alimentos integrales con las aplicaciones clínicas modernas.
Condiciones de salud que Bifidobacterium infantis puede ayudar a apoyar.
Bifidobacterium infantis 35624 has demonstrated efficacy in alleviating IBS symptoms including abdominal discomfort in RCTs, associated with normalization of anti-inflammatory to pro-inflammatory cytokine ratios. Clinical reports confirm patients receiving B. infantis had less abdominal discomfort versus placebo.
Bifidobacterium infantis NLS super strain was evaluated in a randomized double-blind placebo-controlled trial in active celiac disease patients (Smecuol et al., J Clin Gastroenterol 2013). It has also been studied in a registered ClinicalTrials.gov RCT (NCT03271138) specifically for persistent GI symptoms in CeD patients on GFD. In vitro data support its capacity to reduce gliadin-induced intestinal permeability and inflammatory markers.
Bifidobacterium infantis M-63 was part of a tested Bifidobacterium mixture (BB536, M-63, M-16V) in children with seasonal allergic rhinitis and intermittent asthma, showing improved quality of life. It is one of the dominant bifidobacteria in the infant gut, supporting early immune development, and is linked in clinical and mechanistic literature to allergy risk reduction when present in sufficient abundance in early life.
Bifidobacterium infantis is the preeminent early-life gut colonizer in breastfed infants and is uniquely adapted to metabolize human milk oligosaccharides (HMOs). Clinical evidence supports its use in improving infant gut microbiota, reducing intestinal inflammation markers, and supporting gut barrier development. It is considered a foundational probiotic for infant digestive health.
Bifidobacterium infantis is a dominant bifidobacterium in breastfed infant gut microbiome and is incorporated in pediatric probiotic formulations for immune support. Clinical studies of combinations including B. infantis show reduced rates of respiratory infections in infants and young children. It is part of the ProbioKid® formulation with clinical evidence for URTI prevention in children supplemented for 3–9 months.
Bifidobacterium infantis (B. longum subsp. infantis) has been studied for infantile colic due to its key role in establishing healthy gut microbiota in breastfed infants. Infants with colic show reduced Bifidobacteria, and B. infantis supplementation is studied as a corrective probiotic intervention. Multi-strain probiotic preparations containing B. infantis have demonstrated reductions in colic crying duration.
Bifidobacterium infantis (syn. B. longum subsp. infantis) is a probiotic with documented effects on IBS-C including constipation symptoms. A pivotal multicenter RCT (n=362 IBS patients) of B. infantis 35624 demonstrated significant improvement in bowel movement difficulty and constipation vs. placebo. It is among the Bifidobacterium species included in constipation probiotic systematic reviews.
Bifidobacterium infantis is recognized for its role in gut microbiota modulation in infants and has been studied in the context of reducing diarrhea and gastrointestinal disturbances. It is among the Bifidobacterium species included in broader probiotic reviews demonstrating benefit for diarrhea in children.
Bifidobacterium infantis is a component of the VSL#3 multi-strain probiotic studied in diverticular disease remission trials. As part of multi-strain formulations, B. infantis-containing probiotics have demonstrated maintained remission in diverticular disease over 12-month RCTs.
Bifidobacterium infantis is a predominant strain in healthy breastfed infant gut microbiota and has been studied for its role in preventing food allergy and allergic sensitization. Observational studies link reduced B. infantis abundance to increased food allergy risk. It is included in probiotic interventions evaluated for prevention of atopic disease linked to food sensitivity.
Bifidobacterium infantis (B. longum subsp. infantis) is the dominant probiotic species in breastfed infants, with unparalleled HMO-utilization capacity. It is the subject of extensive clinical research demonstrating its role in establishing a healthy infant gut microbiome and reducing gut dysbiosis linked to inflammatory conditions.
Bifidobacterium infantis has been specifically shown to increase plasma tryptophan levels and influence central serotonin transmission, directly linking it to the gut-brain axis. It is classified as a key psychobiotic strain and has shown anti-inflammatory and mood-modulating effects in IBS and stress research.
Bifidobacterium infantis 35624 suppresses histamine-related allergic symptoms and demonstrates strong anti-inflammatory effects. In combination with B. longum BB536 (Lac-B), it significantly decreased histamine levels and suppressed histidine decarboxylase and H1 receptor gene expression. It belongs to Bifidobacteriaceae, which is more abundant in healthy subjects than HIT patients.
Bifidobacterium infantis 35624 (reclassified as B. longum 35624) is the most studied individual probiotic strain specifically for IBS. A 2025 strain-specific meta-analysis (32 articles) confirmed its efficacy for key IBS symptoms. An 8-week RCT with 75 participants demonstrated significant reductions in pain, discomfort, bloating, and constipation. A landmark RCT confirmed it normalizes the gut IL-10/IL-12 cytokine ratio—a unique mechanistic marker for IBS immune dysregulation.
Bifidobacterium infantis 35624 has been studied specifically in IBD and IBS, demonstrating significant immunomodulatory effects including normalization of the IL-10/IL-12 ratio and reduction of systemic and mucosal inflammatory markers in UC patients in controlled trials.
Bifidobacterium infantis is documented in the female urinary microbiome literature as part of the Bifidobacterium genus relevant to urinary tract health. Its use in urogenital probiotic preparations traditionally derives from its role as a beneficial infant intestinal bacterium with systemic protective properties that extend to urinary flora maintenance via gut-urinary axis modulation.
Sistemas corporales que Bifidobacterium infantis puede ayudar a apoyar.
Volver